Romero K - Search Results

1

Evaluation of warfarin drug interaction listings in US product information for warfarin and interacting drugs.

Hines LE, Ceron-Cabrera D, Romero K, Anthony M, Woosley RL, Armstrong EP, Malone DC. Hines LE, et al. Among authors: romero k. Clin Ther. 2011 Jan;33(1):36-45. doi: 10.1016/j.clinthera.2011.01.021. Clin Ther. 2011. PMID: 21397772

2

Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium.

Anthony M, Romero K, Malone DC, Hines LE, Higgins L, Woosley RL. Anthony M, et al. Among authors: romero k. Clin Pharmacol Ther. 2009 Oct;86(4):425-9. doi: 10.1038/clpt.2009.95. Epub 2009 Jul 8. Clin Pharmacol Ther. 2009. PMID: 19587643

3

Time to replace Bazett's QT-correction.

Woosley RL, Romero K. Woosley RL, et al. Among authors: romero k. Pacing Clin Electrophysiol. 2009 Nov;32(11):1379-80. doi: 10.1111/j.1540-8159.2009.02513.x. Epub 2009 Aug 27. Pacing Clin Electrophysiol. 2009. PMID: 19712074 No abstract available.

4

The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases.

Romero K, de Mars M, Frank D, Anthony M, Neville J, Kirby L, Smith K, Woosley RL. Romero K, et al. Clin Pharmacol Ther. 2009 Oct;86(4):365-7. doi: 10.1038/clpt.2009.165. Clin Pharmacol Ther. 2009. PMID: 19763117

5

Medical decision support systems and therapeutics: The role of autopilots.

Woosley RL, Whyte J, Mohamadi A, Romero K. Woosley RL, et al. Among authors: romero k. Clin Pharmacol Ther. 2016 Feb;99(2):161-4. doi: 10.1002/cpt.259. Epub 2015 Oct 22. Clin Pharmacol Ther. 2016. PMID: 26352903

6

CredibleMeds.org: What does it offer?

Woosley RL, Black K, Heise CW, Romero K. Woosley RL, et al. Among authors: romero k. Trends Cardiovasc Med. 2018 Feb;28(2):94-99. doi: 10.1016/j.tcm.2017.07.010. Epub 2017 Aug 1. Trends Cardiovasc Med. 2018. PMID: 28801207 Review.

7

Adverse Drug Event Causality Analysis (ADECA): A Process for Evaluating Evidence and Assigning Drugs to Risk Categories for Sudden Death.

Woosley RL, Romero K, Heise CW, Gallo T, Tate J, Woosley RD, Ward S. Woosley RL, et al. Among authors: romero k. Drug Saf. 2017 Jun;40(6):465-474. doi: 10.1007/s40264-017-0519-0. Drug Saf. 2017. PMID: 28275963 Review.

8

Summary of Torsades de Pointes (TdP) Reports Associated with Intravenous Drug Formulations Containing the Preservative Chlorobutanol.

Woosley RD, Romero K, Heise CW, Gallo T, Tate J, Woosley RL. Woosley RD, et al. Among authors: romero k. Drug Saf. 2019 Jul;42(7):907-913. doi: 10.1007/s40264-019-00804-7. Drug Saf. 2019. PMID: 30888625

9

Assessing cardiovascular drug safety for clinical decision-making.

Woosley RL, Romero K. Woosley RL, et al. Among authors: romero k. Nat Rev Cardiol. 2013 Jun;10(6):330-7. doi: 10.1038/nrcardio.2013.57. Epub 2013 Apr 16. Nat Rev Cardiol. 2013. PMID: 23591268 Review.

10

Clarification to the www.qtdrugs.org updated lists.

Romero K, Woosley RL. Romero K, et al. Pharmacoepidemiol Drug Saf. 2009 May;18(5):423-4. doi: 10.1002/pds.1727. Pharmacoepidemiol Drug Saf. 2009. PMID: 19382150 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

239 results

Search Page

Filters